- Home
- CEE vs ANTX Comparison
CEE vs ANTX Comparison
Compare CEE & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CEE | ANTX |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.1M | 135.4M |
| IPO Year | 1994 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CEE | ANTX |
|---|---|---|
| Price | $17.31 | $3.56 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 20.6K | ★ 3.5M |
| Earning Date | 01-01-0001 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.20 | $1.00 |
| 52 Week High | $19.98 | $6.91 |
Technical Indicators
Market Signals| Indicator | CEE | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.23 | 55.44 |
| Support Level | $16.95 | $1.05 |
| Resistance Level | $18.35 | $6.91 |
| Average True Range (ATR) | 0.72 | 0.92 |
| MACD | -0.11 | -0.10 |
| Stochastic Oscillator | 22.38 | 40.61 |
Price Performance
Historical ComparisonAbout CEE The Central and Eastern Europe Fund Inc. (The)
CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.